Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Gasperini

Showing results (11-20 of 203) with videos related to

Pageof 21
Sort By:
CNS Drugs|September 23, 2023
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2020
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regressionLuca Prosperini, Shalom Haggiag, Carla Tortorella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2024
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world contextLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2021
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple SclerosisLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
European Journal of Neurology|March 3, 2021
Ozone-induced encephalopathy: A novel iatrogenic entityShalom Haggiag, Luca Prosperini, Alessandro Stasolla, et al.
Current Neuropharmacology|August 28, 2025
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis TreatmentMonica Margoni, Luca Battistini, Diego Centonze, et al.
International Journal of Molecular Sciences|June 12, 2019
Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple SclerosisMarta Corsetti, Gabriella Ruocco, Serena Ruggieri, et al.
Journal of Neurology|September 17, 2021
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studiesLuca Prosperini, Carla Tortorella, Shalom Haggiag, et al.
Journal of Neurology|January 5, 2022
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studiesLuca Prosperini, Carla Tortorella, Shalom Haggiag, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 11, 2019
Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled TrialLuca Prosperini, Letizia Castelli, Laura De Giglio, et al.
Pageof 21

Showing results (11-20 of 203) with videos related to

Sort By:
Pageof 21
CNS Drugs|September 23, 2023
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2020
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regressionLuca Prosperini, Shalom Haggiag, Carla Tortorella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2024
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world contextLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2021
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple SclerosisLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
European Journal of Neurology|March 3, 2021
Ozone-induced encephalopathy: A novel iatrogenic entityShalom Haggiag, Luca Prosperini, Alessandro Stasolla, et al.
Current Neuropharmacology|August 28, 2025
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis TreatmentMonica Margoni, Luca Battistini, Diego Centonze, et al.
International Journal of Molecular Sciences|June 12, 2019
Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple SclerosisMarta Corsetti, Gabriella Ruocco, Serena Ruggieri, et al.
Journal of Neurology|September 17, 2021
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studiesLuca Prosperini, Carla Tortorella, Shalom Haggiag, et al.
Journal of Neurology|January 5, 2022
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studiesLuca Prosperini, Carla Tortorella, Shalom Haggiag, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 11, 2019
Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled TrialLuca Prosperini, Letizia Castelli, Laura De Giglio, et al.
Pageof 21